skip to the content

Summary: efficacy of Avastin

  • The key role of angiogenesis in tumour growth and development suggests that the angiogenesis inhibitor Avastin is likely to have potential benefits in the treatment of multiple tumour types
    • numerous controlled clinical trials have demonstrated the efficacy of Avastin in mCRC, mBC, advanced NSCLC and advanced RCC
    • within these tumour types, patients experienced benefit through the addition of Avastin regardless of baseline characteristics or biomarker profile.
  • In clinical trials, Avastin has proven efficacy in combination with a broad range of standard anticancer therapies, including cytotoxic chemotherapy and immunotherapy.